Boots in the U.S.
This article was originally published in The Tan Sheet
Firm will devote an additional $171 mil. (€1=$1.42) to support its three "core" brands - Clearasil, Stepsils medicated lozenges and Nuraphen analgesics - over the next four years. Increased support is part of Boots' effort to boost profit from the $84.9 mil. earned in 2001 to $142.5 mil. by 2005; the additional monies will be split between marketing and new product development, company says. New ads for Clearasil, designed by Grey Global Group, will debut in the U.S. in May and feature a "contemporary" perspective on acne. Four new Clearasil products also are slated to debut stateside later this year, firm notes. Boots acquired Clearasil from P&G in 2000 (1"The Tan Sheet" Oct. 23, 2000, p. 7)...
You may also be interested in...
Boots Healthcare International's acquisition of the Clearasil acne prevention and treatment brand could be a springboard for creating an OTC marketing presence in the U.S.
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.